In making the jump to Alphabet, Ashkenazi is joining one of the few companies larger than Lilly by market value, as the drugmaker’s worth has swelled substantially due to the success of its obesity and diabetes medicines.
But Alphabet brings in significantly more revenue and profit than does Lilly. In the first quarter, Alphabet reported net income of $23.7 billion on revenue of more than $80 billion. Lilly reported net income of $2.2 billion on revenue of about $8.8 billion over the same period.
Google and Alphabet are getting a CFO with a record of “long-term investment to fuel innovation and growth” as the companies navigate the rapid evolution of artificial intelligence, CEO Sundar Pichai said. “I look forward to working with Anat as we invest responsibly to support our next wave of growth,” Pichai said in a statement.
For Lilly, Ashkenazi’s departure adds to a fair bit of turnover in the company’s top leadership. Over the past nine months, the drugmaker has announced the retirement of key executives including the head of its diabetes division, its treasurer, its chief ethics and compliance officer and its executive vice president of global quality.
Lilly said it’s conducting an internal and external search for a new CFO. Ashkenazi will continue to serve on the executive committee as well as maintain her role of CFO through July, Lilly said.
Ashkenazi holds a bachelor’s degree in economics and business administration from Hebrew University and earned her MBA from Tel Aviv University. She will be based in the Bay Area.
By Kristin Jensen
Source: biopharmadive.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
